Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.64 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.55 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17192211 | 0.99 | KCNH2 (0.67) | KCNH2P2RX7HTR2AADRA1DADRA1B | |
| SCHEMBL15748343 | 0.98 | KCNH2 (0.61) | KCNH2P2RX7HTR2AADRA1DADRA1B | |
| SCHEMBL17192209 | 0.88 | KCNH2 (0.63) | KCNH2HTR2AHTR1AHTR2CDRD3 | |
| SCHEMBL17192208 | 0.87 | KCNH2 (0.59) | KCNH2P2RX7HTR2AADRA1DADRA1B | |
| SCHEMBL17192213 | 0.87 | KCNH2 (0.59) | KCNH2HTR2AHTR1A | |
| SCHEMBL17103064 | 0.87 | KCNH2 (0.66) | KCNH2P2RX7HTR2AADRA1DADRA1B | |
| SCHEMBL15748340 | 0.86 | SLC6A2 (0.58) | KCNH2P2RX7HTR2AADRA1DADRA1B | |
| SCHEMBL15748292 | 0.86 | KCNH2 (0.64) | KCNH2P2RX7HTR2AADRA1DADRA1B | |
| SCHEMBL17192210 | 0.84 | P2RX7 (0.54) | KCNH2P2RX7HTR2AADRA1DADRA1B | |
| SCHEMBL15748151 | 0.84 | SIGMAR1 (0.61) | KCNH2P2RX7HTR2AADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802929-B2 | Benzo five-membered nitrogen heterocyclic piperidine or piperazine derivatives and preparation methods and pharmaceutical compositions thereof | SHENYANG HAIWANG BIOTECHNOLOGY CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-9415047-B2 | Use of benzo five-membered nitrogen heterocyclic piperazine or piperidine derivatives | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-20160009703-A1 | BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERIDINE OR PIPERAZINE DERIVATIVES AND PREPARATION METHODS AND PHARMACEUTICAL COMPOSITIONS THEREOF | LIAONING EMMY BIOLOGICAL PHARMACEUTICAL CO., LTD (CN) | 2016-01-14 | — | — | US | disclosed |
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | P2RX5, TBXA2R, CYP3A5 | KCNH2 57/4885P2RX7 22/4885HTR2A 353/4885 |
| US-20160009703-A1 | BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERIDINE OR PIPERAZINE DERIVATIVES AND PREPARATION METHODS AND PHARMACEUTICAL COMPOSITIONS THEREOF | CYP3A5, IL5, ABCC5 | KCNH2 187/4885P2RX7 22/4885HTR2A 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.